New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 27, 2014
06:48 EDTNBIXNeurocrine 8M share Secondary priced at $17.75
The deal size was increased to 8M shares from 7M shares. Jefferies and JPMorgan acted as joint book running managers for the offering.
News For NBIX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 18, 2015
07:12 EDTNBIXNeurocrine coverage assumed with a Buy at Jefferies
Jefferies assumed coverage on Neurocrine with a Buy rating and increased its price target to $61 from $39. The firm expects Neurocrine Phase III data for elagolix and valbenazine over the next 6-9 months, to drive potential regulatory approval and market launch in 2017.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use